CAYIN Technology Brings Its Full Enterprise Signage Portfolio to Booth P1202b, Where Real Deployments Begin

TAIPEI, May 4, 2026 /PRNewswire/ — What does enterprise-grade digital signage look like in practice, across retail floors, hospital lobbies, corporate campuses, and transit hubs? At COMPUTEX 2026, CAYIN Technology invites you to find out firsthand. Visit Booth P1202b, Hall 2, 1F, Nangang Exhibition Center, June 2-5, and experience content management platforms and industrial-grade hardware that have been deployed across more than 100 countries worldwide.

Digital Signage Is No Longer Optional. It Is a Business Driver

The most forward-thinking organizations are not just displaying content. They are using digital signage as an active tool for revenue growth, operational efficiency, and brand consistency. The results are measurable:

• Retail & F&B: Capture attention at the point of decision with real-time promotions and dynamic menus. Reduce campaign turnaround from days to minutes, and cut recurring print costs entirely.
• Corporate & Office: Replace outdated bulletin boards with live announcements, meeting room displays, and wayfinding that adapt to your organization in real time.
• Hospitality: Create arrival moments that guests remember, with lobby displays, event schedules, and personalized welcome messages that set your property apart.

• Healthcare: Ease patient anxiety with clear queue displays, directional guidance, and timely health information. Fewer questions at reception. Smoother patient flow.

• Transportation & Public Spaces: Keep passengers informed with live schedules, platform changes, and emergency alerts, reducing confusion and improving service perception.
   
• Education: Connect students, faculty, and visitors to what matters, from campus news and event boards to lecture hall displays and emergency notifications.

Three Solutions, One Trusted Platform, Built for Your Business

CAYIN’s COMPUTEX 2026 lineup addresses the full spectrum of enterprise deployment needs, from high-demand industrial environments to sustainability-driven organizations:

• Robustie Solution: Built Tough. Built to Last.
  When downtime is not an option, Robustie Solution delivers. Combining industrial-grade CAYIN hardware with CMS-SE, our enterprise content management server, Robustie is engineered for continuous, high-reliability operation across large, multi-site deployments. Centralized management. Consistent performance. No compromises.
   
• Flexie Solution: Your Infrastructure. Your Control.
  Organizations that demand full data sovereignty choose Flexie. Powered by CMS-WS, this self-hosted platform streams content directly from your own hardware to any connected device, browser-based, flexible, and built to meet the most stringent IT security and compliance requirements. Flexie puts you in complete control of your signage network.
   
• E-Paper Solution: Smarter Signage for a Greener Business.
  As ESG commitments move from boardroom pledges to daily operational decisions, E-Paper Solution offers a tangible, measurable path forward. Leveraging e-paper display technology, this ultra-low-power signage platform dramatically reduces energy consumption without sacrificing readability. For organizations serious about reducing their environmental footprint, in retail, logistics, or smart buildings, E-Paper is the signage investment that delivers for your business and your sustainability targets simultaneously.

Your Next Signage Project Starts at Booth P1202b

No two deployments are the same. Whether you are planning your first digital signage rollout, scaling an existing network, or replacing a system that has not delivered, CAYIN’s sales team is at the booth, ready to listen, advise, and map out what integration could look like for your specific environment.

AV system integrators, distributors, resellers, and enterprise IT decision-makers: bring your project brief, your questions, and your challenges. Leave with a clear picture of how CAYIN digital signage fits into your business. Live demonstrations, expert consultations, and real answers, all at Booth P1202b.

Exhibition Details

Event: COMPUTEX 2026
Dates: June 2-5, 2026
Venue: Nangang Exhibition Center, Hall 2, 1F, Taipei
Booth: P1202b

About CAYIN Technology: The Infrastructure Behind the Screen

Behind every screen that never goes dark, there is a platform built to be trusted. CAYIN Technology has been engineering that platform since 2004. Headquartered in Taipei, Taiwan, CAYIN designs and manufactures professional digital signage hardware and software that enterprises in over 100 countries rely on, day in, day out, across retail, hospitality, corporate, healthcare, transportation, and education environments.

Twenty years. One hundred countries. Countless deployments. CAYIN’s track record is not a marketing claim. It is the reason global organizations keep choosing CAYIN as their long-term signage infrastructure partner.

COO steps up as founder Steve Brown passes the baton in planned handover; transition follows a year of record venue wins, SaaS expansion and AI investment

TWYFORD, England, May 4, 2026 /PRNewswire/ — accesso Technology Group (AIM: ACSO), the leading global technology partner to leisure, entertainment and cultural markets, today announced that Lee Cowie has been appointed Chief Executive Officer. The appointment follows a planned leadership transition.

Lee Cowie has been appointed Chief Executive Officer of accesso Technology Group.

Cowie joined accesso as Chief Operating Officer eighteen months ago, bringing with him more than 15 years of senior international experience in technology leadership across the leisure and hospitality sectors. He spent seven years at Merlin Entertainments, most recently as Chief Technology Officer, providing technology leadership across more than 125 visitor attractions in 28 countries. He holds an MBA from Henley Business School and a BSc from Imperial College London.

He succeeds Steve Brown, who founded the company’s namesake accesso business in 2008 and has led the company as CEO in recent years, establishing it as the operational technology backbone for more than 1,100 venues across 31 countries spanning the attractions, ski, hospitality and live entertainment industries.

“This transition has been carefully planned, and I’m leaving the business in very good hands. Accesso has a strong foundation, a talented team and expanding data intelligence capabilities that position it well for its next phase of growth. Lee’s deep experience in this industry, his unique view as a former client, and his understanding of what operators need, makes him the right person to lead the business forward,” said Steve Brown, outgoing CEO, accesso.

“Accesso has spent 25 years building the infrastructure and ecosystem that operators trust with the moments that matter most. My focus from here is on making that infrastructure more intelligent, more connected, and simpler for the operators and visitors who depend on it. The AI era is coming into our industry and we are ready for it,” said Lee Cowie, CEO, accesso.

Cowie’s strategic priorities center on three areas: the development of accesso Intelligence^SM, the company’s AI-powered analytics and forecasting platform built on the acquisition of Dexibit®; an integrated payments strategy designed to simplify transaction economics for operators and visitors; and a programme of integration work across accesso‘s product estate to deliver a connected experience across ticketing, queuing, point of sale, membership and guest experience.

More details about Cowie’s priorities are shared in a blog piece published today on the accesso website.

About accesso Technology Group plc

accesso is the leading global provider of patented and award-winning technology solutions that redefine the guest experience. accesso provides connected ticketing and eCommerce, virtual queuing, restaurant and retail point of sale, distribution, mobile apps and experience management, and data and analytics solutions for more than 1,100 venues worldwide. Its technology helps operators streamline operations, increase revenue and improve the guest journey. accesso delivers a high volume of product enhancements year-round and continuously invests in R&D to help venues and operators adapt to evolving guest needs.

accesso is a public company, listed on AIM: a market operated by the London Stock Exchange. Learn more at accesso.com or follow accesso on X (Twitter), LinkedIn and Facebook.

SINGAPORE, May 4, 2026 /PRNewswire/ — Edwards Lifesciences, the leading global structural heart innovation company, recently announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting.

Valvular heart disease continues to pose a significant and growing burden on healthcare systems across the Asia‑Pacific region. As clinical evidence increasingly supports earlier intervention in the valve disease pathway, the need for long-term durable valve solutions continues to grow.

“By extending the evidence base to 10 years, these data further support the long‑term durability and performance of RESILIA tissue,” said Vikram Jaisinghani, Senior Director, Medical Affairs, Asia‑Pacific, Edwards Lifesciences. “The COMMENCE trial provides prospective, 10‑year durability data that contribute to the evidence base supporting lifetime management for patients with aortic stenosis.”

At 10 years, COMMENCE trial data showed that patients treated with Edwards’ surgical valves featuring RESILIA tissue experienced:

• 97.9% freedom from structural valve deterioration (SVD)
• 97.8% freedom from reoperation due to SVD
• 98.6% freedom from non-structural valve dysfunction (other than PVL)
• Sustained hemodynamic performance, including stable gradients and effective orifice area over time

For patients, long-term durability matters because it can reduce the likelihood of repeat procedures over a lifetime, helping preserve quality of life as life expectancy increases. “As bioprosthetic valves are increasingly used in younger and lower-risk patients, many of whom lead active lifestyles and wish to avoid anticoagulation, plus their ascending life expectancy, long-term durability has become a central consideration in surgical decision-making,” Dato’ Seri Dr. Jeffrey Jeswant Dillon, Senior Consultant Cardiothoracic Surgeon at Institut Jantung Negara (IJN), Kuala Lumpur, Malaysia added. “From a clinical practice perspective, minimal structural valve deterioration observed at 10 years provides important confidence for long‑term treatment planning and may help reduce the need for repeat interventions over a patient’s lifetime.”

Building on nearly 70 years of leadership in structural heart innovation, Edwards has established a strong body of clinical evidence supporting the evaluation of valve performance, durability and treatment options in severe aortic stenosis. Developed more than two decades ago to address the need for improved durability in bioprosthetic valves, RESILIA tissue technology is now incorporated across a broad range of Edwards’ surgical and transcatheter platforms, supporting aortic and mitral surgical valve replacement, aortic valve conduit procedures, and transcatheter treatment in the aortic position.

Within this context, the COMMENCE trial builds on the totality of Edwards’ clinical evidence, further reinforcing the durability of outcomes supporting its surgical and transcatheter therapies, alongside large, randomized, FDA‑approved studies such as the PARTNER series of trials.

The PARTNER trial series advanced the field with long-term patient outcomes on treatment with Edwards TAVR and SAVR, with 10 years of follow-up data. The new COMMENCE trial data build on that foundation with the latest evidence on the long-term durability of RESILIA tissue.

To date, more than 500,000 patients worldwide, including over 30,000 in the Asia‑Pacific region, have been treated with Edwards’ surgical and transcatheter innovations featuring RESILIA tissue¹.

“This significant advancement in tissue technology underscores Edwards’ long-standing commitment to pioneering innovation and advancing long term patient outcomes across Asia-Pacific,” said Amit Raheja, Senior Vice President, Asia‑Pacific, Edwards Lifesciences. “As Asia-Pacific becomes an increasingly important region for Edwards, we continue to invest in clinical evidence and regional capabilities to support sustainable growth and improved patient care. The availability of robust 10-year clinical data helps ensure that clinicians in the region are equipped to make informed treatment decisions that benefit patients over their lifetime.”

About Edwards Lifesciences

Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.

Edwards, Edwards Lifesciences, the stylized E logo, COMMENCE, PARTNER and RESILIA are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

Highlights

• Median Tmax of 10 minutes for SPONTAN^® (5 mg) versus 60 minutes for oral vardenafil (20mg), consistent with Phase I study.
• Interim data provide the key pharmacokinetic dataset requested by the FDA, including rapid absorption, repeat-dose profile, with no drug accumulation observed, and consistent pharmacokinetics across adult and geriatric populations.
• Pharmacokinetic profile in subjects ≥65 years comparable to adults in the dataset, addressing a key FDA Pre-IND requirement.
• Consistent safety profile observed, with no serious adverse events, no Grade 3 or 4 treatment-emergent adverse events, and no treatment-related discontinuations.
• No drug accumulation observed following five days of repeat intranasal dosing (5 mg).
• Interim data are expected to inform the Company’s planned FDA 505(b)(2) regulatory pathway.
• Final results, including full statistical analysis, expected Q3 CY2026.

SYDNEY, May 4, 2026 /PRNewswire/ — LTR Pharma Limited (ASX:LTP) (“LTR Pharma“ or “the Company”) reports interim Phase II pharmacokinetic (PK) and safety data for SPONTAN^®, demonstrating a rapid time to peak concentration (median Tmax 10 minutes) and a consistent safety profile, with no serious or severe treatment-emergent adverse events observed. The data support the Company’s planned FDA 505(b)(2) regulatory pathway, subject to completion of final statistical analysis.

These results indicate a pharmacokinetic profile distinct from oral PDE5 inhibitors, consistent with rapid-onset, on-demand use.

The interim results indicate that the Study has characterised the key pharmacokinetic parameters requested by the FDA, including rapid absorption, repeat-dose behaviour, and consistency across adult and geriatric populations, subject to final statistical analysis.

The treatment phase of the Study has been completed, and a preliminary analysis of the data has been undertaken. The analysis demonstrates a rapid-onset pharmacokinetic profile and favourable safety in both adult and geriatric populations. The Study was designed in accordance with FDA Pre-IND guidance and supports LTR Pharma’s planned 505(b)(2) development pathway.

Statistical analysis of the dataset is ongoing. Full results, including final pharmacokinetic, safety, and dose-proportionality analyses, are expected to be released in Q3 CY2026.

Key Metrics: Interim Phase II Pharmacokinetic Data

The data are interim and based on 27 subjects. Final statistical analysis remains ongoing. Cmax values expressed as mean ± standard deviation. n.a. = not applicable. Observed lower Cmax relative to oral vardenafil is consistent with the lower dose, while maintaining rapid systemic exposure.

Study Findings

The treatment phase of the SPONTAN Phase II clinical study has been completed, and a preliminary analysis of the data has been undertaken. The primary objectives of the Study, as agreed with the FDA, were to characterise single- and multiple-dose pharmacokinetics of intranasally delivered vardenafil (SPONTAN), to evaluate the effect of intranasal delivery on drug accumulation following repeat dosing, and to assess pharmacokinetic differences between adult and geriatric populations.

Onset of action. SPONTAN (5 mg vardenafil) demonstrated a median Tmax of 10 minutes, compared with a median Tmax of 60 minutes for the 20 mg vardenafil oral tablet. The Tmax range for SPONTAN (5 mg) was 10–15 minutes, compared with 30–180 minutes for the oral tablet.

Geriatric profile. Pharmacokinetic profiles in subjects ≥65 years were comparable to those in the adult cohort, with no apparent differences observed in the dataset, and the median Tmax of 10 minutes for SPONTAN (5 mg) was maintained across both age groups. These findings address a key FDA requirement and may support use across age groups.

Drug accumulation. Intranasal administration of SPONTAN (5 mg) over five consecutive days did not result in drug accumulation, with an accumulation ratio of 1.0 ± 0.9, consistent with the multiple-dose study objectives agreed with the FDA.

Safety and tolerability. Preliminary safety analysis did not identify any new or unexpected treatment-emergent adverse events. Across all three dose groups, no serious adverse events, no Grade 3 or 4 treatment-emergent adverse events, and no treatment-related discontinuations were observed in the interim dataset.

Clinical and Commercial Relevance

Oral PDE5 inhibitors require advance planning, with onset times ranging from approximately 30 minutes to over 2 hours. Dropout rates exceeding 50% have been reported in the published literature, with lack of spontaneity a consistently cited reason for discontinuation.^[1]

The data indicate a rapid-onset profile relative to oral PDE5 inhibitors, which may be relevant for patient adherence given reported discontinuation rates associated with delayed onset. Consistent pharmacokinetics in the geriatric cohort may be relevant across age groups, subject to final analysis and regulatory review.

Regulatory Pathway

The Phase II PK Study was specifically designed in accordance with FDA Pre-IND guidance and is a key requirement in LTR Pharma’s FDA 505(b)(2) development pathway. The data are expected to inform LTR Pharma’s planned regulatory strategy, including the proposed 505(b)(2) submission in the United States, subject to completion of final analysis and regulatory feedback.

Data Status and Limitations

The data reported in this announcement are based on 27 subjects who completed the dosing phase of the Phase II PK Study and reflect a preliminary analysis. Final statistical analysis, including dose proportionality, full pharmacokinetic modelling, and the complete safety dataset, remains ongoing. The final dataset and statistical conclusions may differ from the interim observations reported. Full study results are expected to be released in Q3 CY2026.

Study Design

Figure 1: SPONTAN Phase II study design. Randomised, three-way crossover (Part 1) followed by multiple-dose evaluation (Part 2).

The Study design, including endpoint selection and the inclusion of a robust geriatric cohort, was agreed upon with the FDA during the Pre-IND meeting in 2025.

LTR Pharma Executive Chairman, Lee Rodne, said:

“The interim Phase II data are consistent with our Phase I findings and reinforce SPONTAN’s differentiated rapid-onset profile, including in men aged 65 and over, a group that often requires dose adjustment with oral PDE5 therapies. Importantly, no serious adverse events, no severe treatment-emergent events, and no treatment-related discontinuations were observed. This Study was specifically designed in accordance with FDA Pre-IND guidance, and we are now focused on completing the statistical analysis and progressing our 505(b)(2) regulatory strategy in the United States.”

Next Steps

LTR Pharma, in collaboration with its Clinical Research Organisation, will complete the final statistical analysis over the coming months, with full Study results expected to be released in Q3 CY2026. The complete dataset will be used to support LTR Pharma’s planned FDA 505(b)(2) submission and ongoing regulatory engagement in Australia, the United States, and other key markets.

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant unmet medical needs through its proprietary intranasal drug-delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.

LTR’s lead products, SPONTAN^® and ROXUS^®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW^®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function. 

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.

LTR Pharma Investor Centre

Stay informed with LTR Pharma’s latest announcements and market updates by visiting our Investor Centre.

HONG KONG, DUBAI, UAE and SINGAPORE, May 4, 2026 /PRNewswire/ — From April 21 to 23, 2026, at Money20/20 Asia 2026—one of the most influential fintech events in the Asia-Pacific region—Cregis participated as an exhibitor at Booth 6001. The conference brought together industry leaders to discuss key themes such as payment innovation, cross-border settlement, digital assets, and regulatory developments. During the event, Cregis presented its comprehensive digital asset infrastructure solutions tailored for enterprises and financial institutions, while engaging in in-depth conversations with participants from banks, payment providers, fintech companies, and Web3 organizations.

Advancing Payment Infrastructure

Throughout the event, the Cregis team highlighted its end-to-end capabilities in on-chain payments and digital asset management, with a focus on enterprise payment and treasury needs. As stablecoins and blockchain technologies increasingly move into real-world applications, enterprise priorities are shifting from simply supporting crypto assets to enabling efficient, secure, and controllable fund flows.

Cregis offers a unified infrastructure that supports multi-chain and multi-asset management, adaptable to a wide range of use cases including cross-border trade settlement, merchant payments, and corporate treasury operations. By ensuring both security and compliance, the platform enables more efficient global fund movement and greater transparency in settlement processes.

Richard, Co-Founder of Cregis, commented during the event: “Today, the key challenge for enterprises is no longer whether to enter the digital asset space, but how to build a fund management system that balances efficiency, security, and compliance. Through our infrastructure, we aim to help businesses operate more effectively in an increasingly complex global payments landscape.”

A New Cross-Border Payment Paradigm Driven by Stablecoins

Stablecoins and on-chain payments emerged as central topics at this year’s conference. As more financial institutions and payment providers explore the use of digital assets in cross-border settlement, stablecoins are becoming a critical bridge between traditional finance and the crypto economy.

During the event, Cregis engaged with various industry partners to discuss practical applications of stablecoins in cross-border trade, enterprise settlement, and treasury management. Compared to traditional cross-border payment rails, stablecoin-based settlement offers clear advantages in efficiency, cost, and transparency. At the same time, it raises higher requirements for underlying infrastructure, particularly in areas such as secure custody, fund monitoring, and regulatory compliance.

Engaging Industry Leaders: Exploring the Future Evolution of Finance in Asia

Beyond its presence on the exhibition floor, Cregis co-hosted a side event titled The Reserved Table: Redefining Asia’s Future of Settlements alongside WIDTH, StraitsX, and PlatON. The event brought together key players across payments, stablecoins, and cross-border settlement to explore the future trajectory of financial infrastructure in Asia.

At the event, Tannie, Head of Southeast Asia at Cregis, joined a panel discussion themed “A New Standard of Value: Stablecoins, Settlement & the New Money Stack”, where he shared insights from frontline enterprise use cases.

Tannie noted that the market still tends to view stablecoins primarily as a “product”, such as a yield-generating tool or trading instrument. However, in real-world business scenarios, stablecoins are increasingly evolving into foundational infrastructure. For exchanges, payment providers, and cross-border enterprises, the focus is no longer on yield, but on critical operational questions: how to enable real-time global settlement, how to manage liquidity across regions, and how to reduce reliance on traditional banking systems.

Looking ahead, Tannie emphasized that the deeper significance of stablecoins lies in their ability to fundamentally reshape how enterprises manage capital. Within an infrastructure-driven stablecoin framework, businesses can achieve:

• Policy-based approval and signing mechanisms for fund movements
• Real-time on-chain reconciliation and automated settlement
• A unified liquidity view across multiple chains and wallets
• 24/7 uninterrupted treasury operations

This shift signals that stablecoins are not merely replacing traditional payment rails—they are driving enterprises to transition from conventional financial workflows toward a more programmable, automated “next-generation operating system for capital.”

From Payment Capabilities to Global Financial Connectivity

As stablecoins, on-chain payments, and enterprise-grade asset management systems continue to mature, a more efficient, transparent, and globally connected financial network is taking shape.

Richard noted: “In the coming years, as the convergence between traditional finance and Web3 accelerates, demand for robust digital asset infrastructure will continue to grow. Cregis aims to be a key enabler in this transition, providing enterprises with secure, scalable, and reliable foundational capabilities.”

Looking ahead, Cregis will continue to enhance its product offerings across custody, payments, and asset management. By focusing on real-world business needs, the company is committed to building a more comprehensive digital asset infrastructure, empowering global enterprises to improve efficiency, manage risks, and achieve sustainable growth in the next generation of financial systems.

SINGAPORE, May 4, 2026 /PRNewswire/ — The Motion Picture Association (MPA) today announced the appointment of Paul Muller as Vice President, Production Policy, Asia‑Pacific.

In this role, Muller will lead the MPA’s engagement with governments across the Asia‑Pacific region to advance policies that support the production of local and international film and television, strengthening the region’s position as a globally competitive production hub. He will report to Trevor Fernandes, Senior Vice President & Deputy Managing Director, Head of Policy & Government Affairs, Asia‑Pacific.

Muller brings deep regional expertise to the role and will continue to serve concurrently as Chief Executive Officer of the MPA’s local office, Australia New Zealand Screen Association (ANZSA), where he has been a leading advocate for screen production policy reform.

Urmila Venugopalan, President and Managing Director, Asia‑Pacific, Motion Picture Association, welcomed the appointment. “Paul has made an outstanding contribution to production policy in Australia and New Zealand, delivering tangible outcomes for governments, local screen communities and our member studios,” said Venugopalan. “His leadership has helped unlock record levels of investment, grow skilled workforces and position both markets as premier destinations for local and international production. We’re delighted to have Paul take on this expanded regional role at a time when shaping production policy is central to the growth of the screen industry across Asia‑Pacific.”

During his tenure at ANZSA, Muller has been a key advocate for improvements to Australia’s screen production incentive system, contributing to a record AUD$2.6 billion investment in scripted screen content. In New Zealand, his work to support a more streamlined incentive framework underpinned NZD$1.25 billion in international production investment, helping expand employment and skills across the screen sector.

Muller said he was honoured to be appointed to the regional role. “I’m grateful for the opportunity to take on this position and excited to work more closely with governments across the Asia‑Pacific region,” said Muller. “The region has extraordinary creative talent and production capability, and I’m committed to doing everything I can to support policies that enable sustainable growth and deliver the best outcomes for the screen community across the entire region.”

Prior to joining ANZSA, Muller held senior commercial leadership roles in the global entertainment industry, including Vice President & Managing Director of Paramount Home Media Distribution Australia for a decade. Earlier in his career, he held senior marketing and sales roles at EMI Music and Universal Music in the Netherlands, following earlier experience at Procter & Gamble. He holds Master’s degrees in Business Administration and Civil Engineering.

The Motion Picture Association’s member studios are Netflix, Paramount Pictures, Sony Pictures, Universal Studios, The Walt Disney Studios, Prime Video & Amazon MGM Studios, and Warner Bros. Discovery. Charles Rivkin is Chairman and CEO.